ABSCF:OTC-AB Science S.A (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 9.90

Change

0.00 (0.00)%

Market Cap

USD 0.45B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TKPHF Takeda Pharmaceutical Company ..

N/A

USD55.18B 139.80 0.14
MKGAF MERCK Kommanditgesellschaft au..

-2.30 (-1.84%)

USD54.46B 29.26 14.44
MKKGY MERCK Kommanditgesellschaft au..

+0.12 (+0.49%)

USD54.00B 30.50 14.85
ESALF Eisai Co., Ltd

+1.01 (+1.28%)

USD22.95B 20.08 0.13
ESALY Eisai Co., Ltd

+3.64 (+4.60%)

USD22.62B 20.02 0.13
SGIOY Shionogi & Co., Ltd

-0.10 (-0.64%)

USD17.67B 16.78 0.08
SGIOF Shionogi & Co., Ltd

-0.60 (-1.01%)

USD17.67B 17.27 0.08
TEVJF Teva Pharmaceutical Industries..

N/A

USD12.78B 483.60 27.69
SFOSF Shanghai Fosun Pharmaceutical ..

-0.01 (-0.28%)

USD12.18B 18.99 2.54
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ABSCF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 67.80% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.80% 85% B 84% B
Trailing 12 Months  
Capital Gain 85.39% 91% A- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.39% 89% B+ 86% B
Trailing 5 Years  
Capital Gain -40.79% 56% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.79% 56% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -10.47% 16% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.47% 16% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 43.49% 80% B- 67% D+
Risk Adjusted Return -24.07% 9% F 8% F
Market Capitalization 0.45B 88% B+ 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -29.58 91% A- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 157.25% 92% A- 95% A
Return on Assets -54.29% 24% F 18% F
Debt to Equity Ratio -38.03% 84% B 90% A-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.87 55% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector